Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
The accelerated blood clearance (ABC) phenomenon accounts for the rapid systemic clearance of PEGylated nanocarriers upon repeated administrations. IgM production against the polyethylene glycol (PEG) coating in PEGylated liposomes is now known to be responsible for such unexpected pharmacokinetical alterations. The ABC phenomenon poses a remarkable clinical challenge by reducing the therapeutic efficacy of encapsulated drugs and causing harmful effects due to the altered tissue distribution pattern of the drugs. In this study, we investigated the in vivo performance of liposomes modified with polyglycerol (PG) upon repeated injection, and the in vivo therapeutic efficacy of such liposomes when they encapsulated a cytotoxic agent, doxorubicin (DXR). Repeated injection of PEG-coated liposomes in rats induced the ABC phenomenon, while repeated injection of PG-coated liposomes did not. In addition, DXR-containing PG-coated liposomes showed antitumor activity that was superior to that of free DXR and similar to that of DXR-containing PEG-coated liposomes upon repeated administration. These results indicate that polyglycerol (PG) might represent a promising alternative to PEG via enhancing the in vivo performance of liposomes by not eliciting the ABC phenomenon upon repeated administration.
Department of Pharmacokinetics and Biopharmaceutics, Subdivision of Biopharmaceutical Sciences, Institute of Health Biosciences, The University of Tokushima, 1-78-1, Sho-machi, Tokushima 770-8505, Japan; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
Amr S
AS
Abu Lila
Kosuke
K
Nawata
Taro
T
Shimizu
Tatsuhiro
T
Ishida
Hiroshi
H
Kiwada
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy / Q000473:pathology; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000008:administration & dosage; D005990:Glycerol / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D007075:Immunoglobulin M / Q000097:blood; D008081:Liposomes / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010714:Phosphatidylethanolamines / Q000737:chemistry; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D011108:Polymers / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar; D047368:Tumor Burden / Q000187:drug effects
D000970:Antineoplastic Agents; D007075:Immunoglobulin M; D008081:Liposomes; D010714:Phosphatidylethanolamines; D011108:Polymers; C038089:1,2-distearoylphosphatidylethanolamine; C043941:polyglycerol; D011092:Polyethylene Glycols; D004317:Doxorubicin; D005990:Glycerol
(3)H-CHE(3); 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy(polyethylene glycol)-2000]; 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-n-[polyglycerine-(610, 760, 1500 or 2980)]; ABC; AUC; Accelerated blood clearance (ABC) phenomenon; Anti-PEG IgM; CHOL; DMEM; DXR; Dulbecco's modified Eagle's medium; ELISA; FBS; H-cholesterylhexadecyl ether; HEPC; HRP; MPS; PEG; PG; PG(610, 760, 1500 or 2980)-DSPE; PL; Polyethylene glycol (PEG); Polyglycerine (PG); Repeated administration; accelerated blood clearance; area under the blood concentration–time curve; cholesterol; doxorubicin; enzyme-linked immunosorbent assay; fetal bovine serum; horseradish peroxidase; hydrogenated egg phosphatidylcholine; mPEG(2000)-DSPE; mononuclear phagocyte system; phospholipid; polyethylene glycol; polyglycerine